DelveInsight’s, Non-Small-Cell Lung cancer Pipeline Insight, 2022,” report provides comprehensive insights about 135+ companies and 150+ pipeline drugs in Non-Small-Cell Lung cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Non-Small-Cell Lung cancer Pipelinereport, detailed description of the drug is given which includes mechanism of action of the drug, Non-Small-Cell Lung cancer Pipelineclinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small-Cell Lung cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Non-Small-Cell Lung cancer Pipeline Report
Recent Developmental Activities in the Non-small Cell Lung Cancer Pipeline
Request a sample and discover the recent breakthroughs happening NSCLC pipeline landscape @ Non-small Cell Lung Cancer Pipeline Report
Non-small Cell Lung Cancer Overview
Non-small-cell lung cancer is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs. About a quarter of lung cancers are this kind. c) Large cell (undifferentiated) cancer grows and spreads more quickly. That can make it tougher to treat. It’s about 10% of lung cancers. An effective treatment for non-small cell adenocancer depends on the cancer’s stage. Surgery to remove all or only part of the lung is usually required if the cancer hasn’t spread.
Non-Small-Cell Lung cancer Emerging Drugs
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of three leading ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG13 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.
JDQ443: Novartis
JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with advanced non-small cell lung cancer (NSCLC).
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, as the KRASG12C protein regenerates every 24–48 hours. Adagrasib is being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer and pancreatic cancer.
INBRX-106: Inhibrx
INBRX-106 is a hexavalent product candidate agonist of OX40. OX40 is a co-stimulatory receptor expressed on immune cells that is enriched in the tumor microenvironment. OX40 ligand is a trimeric protein that activates OX40 signaling through clustering. INBRX-106 was engineered to bind and cluster six OX40 receptors and has been shown preclinically to significantly outperform bivalent antibodies in co-stimulatory capacity and anti-tumor activity.
Non-Small-Cell Lung cancer Pipeline Therapeutic Analysis
There are approx. 135+ key companies which are developing the therapies for Non-Small-Cell Lung cancer (NSCLC). The companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.
Learn more about the NSCLC emerging pipeline therapies @ Non-small Cell Lung Cancer Clinical Trials
Non-small Cell Lung Cancer Pipeline Therapies and Key Companies
Non-small Cell Lung Cancer Pipeline Therapeutics Assessment
Dive deep into rich insights for NSCLC emerging therapies and assessment, visit @ Non-small Cell Lung Cancer Emerging Therapies
Scope of the Non-small Cell Lung Cancer Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
For further information on the NSCLC current pipeline therapeutics, reach out to @ Non-small Cell Lung Cancer Treatment
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/